Squibb CNS R&D agreement
Firm announced it has signed an agreement with the Danish firm, Ferrosan A/S "to cooperate on research for new agents affecting the central nervous system." Squibb said Ferrosan is "renowned for its expertise and experience in neuropharmacology".
You may also be interested in...
Keeping Track: Submissions Galore Start The New Year; US FDA Clears New Indications For Enhertu, Xalkori
The latest drug development news and highlights from the Pink Sheet US FDA Performance Tracker
Vacci Prep is first “supplement to establish a standard of care for consumers when preparing their immune system for vaccinations,” Dentovations says.
Effective medical device regulation supports both safety and innovation needs. This article assesses how well the US FDA and the Australian TGA achieve this balance.